The multikinase inhibitor RXDX-105 is effective against neuroblastoma in vitro and in vivo

Neuroblastoma is the most common extracranial solid tumor of childhood and accounts for 15% of all pediatric cancer-related deaths. New therapies are needed to improve outcomes for children with high-risk and relapsed tumors. Inhibitors of the RET kinase and the RAS-MAPK pathway have previously been...

Descripción completa

Detalles Bibliográficos
Autores principales: Flynn, Sean M., Lesperance, Jacqueline, Macias, Andrew, Phanhthilath, Nikki, Paul, Megan Rose, Kim, Jong Wook, Tamayo, Pablo, Zage, Peter E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2019
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6824878/
https://www.ncbi.nlm.nih.gov/pubmed/31695841
http://dx.doi.org/10.18632/oncotarget.27259

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6824878/
https://www.ncbi.nlm.nih.gov/pubmed/31695841
http://dx.doi.org/10.18632/oncotarget.27259

Ejemplares similares